Fate therapeutics announces worldwide collaboration with janssen for novel ipsc-derived cell-based cancer immunotherapies

ꟷ collaboration leverages company’s ipsc product platform and janssen’s proprietary tumor-targeting antigen binders to create novel car nk and car t-cell...

FATE Ratings Summary

FATE Quant Ranking